Trine Jakobi Nøttrup, MD, PhD, on BRCA Wild-Type Recurrent Ovarian Cancer: Novel Triplet Maintenance Regimen
Trine Jakobi Nøttrup, MD, PhD, of Rigshospitalet, describes findings from the DOVACC trial, which evaluated the combination of olaparib, durvalumab, and UV1—a therapeutic cancer vaccine directed against human telomerase reverse transcriptase—as maintenance therapy in patients with BRCA wild-type recurrent ovarian cancer (Abstract LBA39).
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
First-line pembrolizumab monotherapy significantly improved progression-free survival compared with carboplatin plus paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial cancer, according to an interim analysis of the phase III...
Domenica Lorusso, MD, PhD, on Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer
Domenica Lorusso, MD, PhD, of Humanitas University, summarizes findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 study, which showed sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate, provided statistically significant and clinically meaningful improvements in progression-free and overall survival and response vs treatment of physician’s choice in patients with previously treated advanced or recurrent endometrial cancer, with manageable safety (Abstract LBA11).
Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer
Neoadjuvant niraparib monotherapy produced tumor responses and enabled complete resection in selected patients with homologous recombination deficiency (HRD)-positive advanced ovarian cancer who were considered unlikely to achieve complete primary debulking surgery. Dan Liu, MD, and colleagues...
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
Machine learning models using routine clinical data may be able to identify individuals at higher risk of developing several common cancers, according to findings from an international study presented at the ESMO Congress 2026 (Abstract 280RO). “For selected cancers, these models could serve as a...
ESMO 2026: Sacituzumab Tirumotecan vs Physician’s Choice of Treatment in Patients With Previously Treated Endometrial Cancer
Sacituzumab tirumotecan may extend both progression-free and overall survival compared with standard chemotherapy in patients with advanced or recurrent endometrial cancer, according to findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 trial presented at the ESMO Congress 2026 (Abstract...
Immunotherapy/PARP Inhibitor Combination Prolongs Survival in Advanced Endometrial Cancer
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson...
Shannon N. Westin, MD, on Advanced or Recurrent Endometrial Cancer: DUO-E/GOG-3041/ENGOT-EN10
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, reviews interim overall survival and safety results from a randomized phase III study evaluating durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with advanced/recurrent endometrial cancer (Abstract LBA37).
Brian M. Slomovitz, MD, on dMMR Advanced or Recurrent Endometrial Cancer: KEYNOTE-C93/GOG-3064/ENGOT-en15
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, discusses results from a phase III, randomized, open-label study of first-line pembrolizumab vs carboplatin/paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial carcinoma (Abstract LBA12).
ASCO Issues Its First Living Guideline on Systemic Treatment of Recurrent Ovarian Cancer
In June 2026, an ASCO Expert Panel voted to approve ASCO’s first Living Guideline on systemic treatment of ovarian cancer recurrence.1 The continuously updated, evidence-based guideline addresses patients with epithelial ovarian cancer, primary peritoneal carcinoma, and fallopian tube carcinoma,...
Mocertatug Rezetecan Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
First results from the global phase I BEHOLD-1 study suggest that the investigational B7-H4–targeted antibody-drug conjugate mocertatug rezetecan showed activity in two difficult-to-treat gynecologic cancers: platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.1 At the...
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Survival and mortality disparities for women with breast cancer are widening between rural and urban areas over time, according to findings from two American Cancer Society studies presented at the 2026 ASCO Quality Care Symposium (Abstracts 208 and 253). The studies found that women from rural...
The Wistar Institute Names New President and Chief Executive Officer
The Wistar Institute’s Board of Trustees has appointed Ronny Drapkin, MD, PhD, a physician-scientist and ovarian cancer researcher at the University of Pennsylvania Perelman School of Medicine, to be the Institute’s next President and Chief Executive Officer, effective November 30, 2026. Dr....
ACS Report Highlights Cancer Burden and Screening Disparities in U.S. Hispanic Population
The cancer distribution in the Hispanic population is distinct from the general population in the United States, according to a statistics report from the American Cancer Society (ACS) published in CA: A Cancer Journal for Clinicians. The report indicated fewer lung and urinary bladder cancers,...
Residual Ovarian Cancer Risk in BRCA Carriers May Inform Timing of Preventive Surgery
Among older BRCA carriers who remain in good health, the residual risk of ovarian cancer may be high enough to support consideration of preventive surgery, according to findings from a prospective cohort study reported in JAMA Surgery. Giannakeas et al also found that BRCA1 carriers who defer...
Pembrolizumab/Olaparib Strategy in BRCA-Nonmutated Advanced Ovarian Cancer
A pembrolizumab/olaparib strategy significantly improved progression-free survival in patients with newly diagnosed BRCA-nonmutated advanced epithelial ovarian cancer, although overall survival was not improved. Ignace Vergote, MD, PhD, and colleagues reported results from the phase III...
I Wasn’t Expecting Cancer at 22
Before I was diagnosed with advanced stage ovarian ependymoma, in 2025, when I was just 22, I didn’t know anything about cancer. I knew a few older adults who had had cancer, but that was the extent of my knowledge about the disease. Even to this day, I’m not sure I’ve completely wrapped my head...
KEYNOTE-826: Long-Term Outcomes With Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
Five-year follow-up from the phase III KEYNOTE-826 trial suggests a durable benefit with first-line pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, in patients with recurrent or metastatic cervical cancer, according to Hasegawa et al in JAMA Oncology. At the first...
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
According to the results of a retrospective analysis reported by Jeong et al in JCO Precision Oncology, early molecular response assessed using circulating tumor DNA (ctDNA) was associated with radiographic response and longer time to progression among patients with recurrent high-grade serous...
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
Cervical cancer remains a preventable cause of morbidity and mortality, particularly among women who are not reached by screening programs. In a research letter published in JAMA Network Open, Sonawane et al emphasized the importance of identifying those who have never been screened and reported...
Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery
A short-term, intensive weight-loss program before surgery was feasible and produced meaningful weight loss in women with endometrial cancer and excess weight in the randomized ENDO-CARE trial. The intervention was also associated with fewer postoperative complications, although the study was not...
Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer
Single-agent rezatapopt produced “very deep and durable responses” in heavily pretreated patients with TP53 Y220C–mutated advanced ovarian cancer, according to updated results from the pivotal phase II PYNNACLE trial presented at the 2026 ASCO Breakthrough meeting in Singapore. The analysis was...
Residential Social Vulnerability Associated With Worse Survival Among Black Women With Epithelial Ovarian Cancer
Residential context showed a significant relationship with survival among Black women diagnosed with epithelial ovarian cancer, according to study findings published in JAMA Network Open. Black women who lived in more socially vulnerable communities faced higher risks of death than those in less...
Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy
Researchers from the University of Texas MD Anderson Cancer Center have discovered a mechanism of donor subset–driven chimeric antigen receptor (CAR) natural killer (NK) dysfunction and have developed a manufacturing strategy for improving the antitumor potency of CAR NK cell therapies for patients ...
How Do Surgical Ovarian Cancer Prevention Strategies Compare for Sexual Function?
In a prospective, multicenter, nonrandomized patient-preference trial published in JAMA Network Open, interval salpingectomy with delayed oophorectomy (ISDO) was associated with less impairment in sexual function than risk-reducing salpingo-oophorectomy (RRSO) among premenopausal women at high risk ...
Emergency Hospital Admission Accounts for 40% of Ovarian Cancer Diagnoses in England
About two in five women diagnosed with ovarian cancer were only diagnosed after an emergency admission to the hospital, according to the results of a national population-based study from England that was published in BMJ Oncology. “The risk of being diagnosed with ovarian cancer after an emergency ...
Disparities in Cancer Screening Persist Among Sexual Orientation and Gender Identity Minority Populations
New research has uncovered persistent disparities in preventive cancer care across different sexual orientation and gender identity (SOGI) minority populations. The study—published by Arena et al in the journal Cancer—found particular concern for cervical and breast cancer screening. To assess SOGI ...
Doublet in Low-Risk Gestational Trophoblastic Tumors
In a French phase I/II trial (TROPHAMET) reported in JAMA Oncology, You et al found that first-line avelumab plus methotrexate was associated with high efficacy in patients with low-risk gestational trophoblastic tumors. Study Details In the multicenter study, 27 patients with low-risk gestational...
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer
Four-year follow-up from the phase III RUBY clinical trial showed durable long-term benefit with front-line dostarlimab-gxly, a PD-1 blocker, plus carboplatin/paclitaxel in patients with mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) primary advanced or recurrent endometrial ...
GLP-1 RAs May Reduce Risk of Obesity-Related Cancers
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with a 41% lower risk of developing obesity-associated cancers in the short term for obese, nondiabetic patients, according to findings from an observational study published in Annals of Oncology. “Our study found that...
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
Patient-reported outcomes from a subgroup analysis of the final analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial showed that first-line maintenance therapy with the PARP inhibitor niraparib did not adversely affect overall health-related quality of life in patients with newly diagnosed...
Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer
Final overall survival results from the phase III ROSELLA trial showed a statistically and clinically significant survival benefit with the selective glucocorticoid receptor antagonist relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer....
Early Ovarian Cancer: Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival
In a retrospective cohort study reported as a research letter in JAMA Oncology, Matsuo et al found an increasing use of minimally invasive surgery (MIS), an association of MIS with intraoperative capsule rupture, and an association of capsule rupture with poorer survival in patients with early...
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
Hundreds of thousands of people diagnosed with cancer are still alive today, but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those diagnosed today to carry a germline...
Case 3: Newly Diagnosed Advanced Uterine Papillary Serous Carcinoma
This is Part 3 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Krishnansu Tewari, Noelle Cloven, and Alyssa Bujnak discuss the management of advanced uterine papillary serous carcinoma with mismatch repair proficiency (MMRp). The patient is a 72-year-old woman presenting with postmenopausal vaginal bleeding, abdominal discomfort, and cul-de-sac nodularity. She is ultimately diagnosed with FIGO stage IVB uterine papillary serous carcinoma that is MMRp and p53-positive, with upper abdominal metastases confirmed at surgical exploration. The faculty explore the rationale for primary debulking surgery vs neoadjuvant chemotherapy in patients with advanced uterine serous carcinoma, and how comprehensive biomarker testing—including MMR status, p53, POLE, and HER2—can further stratify prognosis and guide treatment within the MMRp population. They also discuss the emerging role of circulating tumor cell-free DNA as a monitoring tool in endometrial cancer and highlight novel clinical trials that may offer additional options for this high-risk patient population.
Case 2: Newly Diagnosed Advanced MMRp Endometrioid Adenocarcinoma
This is Part 2 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Krishnansu Tewari, Noelle Cloven, and Alyssa Bujnak discuss the management of newly diagnosed advanced endometrial cancer with mismatch repair proficiency (MMRp). The patient is a 66-year-old woman presenting with postmenopausal vaginal bleeding, significant anemia, and moderate back pain. Following surgery, she is diagnosed with a FIGO stage IV grade 3 MMRp endometrioid adenocarcinoma with residual measurable nodal disease. The faculty explore the surgical vs neoadjuvant approach in patients with metastatic disease complicated by active bleeding, and how to select between pembrolizumab and dostarlimab when considering front-line chemo-immunotherapy regimens. They also debate whether immunotherapy should be reserved for the recurrent setting in MMRp patients or used upfront, and discuss the role of emerging clinical trials that aim to improve outcomes in this population through novel antibody-drug conjugate combinations.
Case 1: Advanced and Recurrent MMRd Endometrioid Adenocarcinoma of the Uterus
This is Part 1 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Krishnansu Tewari, Noelle Cloven, and Alyssa Bujnak discuss the management of advanced and recurrent endometrial cancer in the context of immunotherapy. The patient is a 58-year-old woman who presents with 6 months postmenopausal vaginal bleeding and mild, diffuse abdominal discomfort and constipation. She has a history of well-controlled hypertension and non–insulin-dependent diabetes, and a family history of colorectal cancer. Following robotic surgery with sentinel lymph node mapping, she is ultimately diagnosed with a stage IIIC1 grade 2 mismatch repair–deficient (dMMR) endometrioid adenocarcinoma The faculty explore how molecular profiling informs adjuvant treatment decisions and how to apply evolving clinical trial data, FDA labeling, and guidelines to patients without measurable disease. They also address the challenges of managing recurrent disease after front-line immunotherapy, including the potential role of clinical trials and novel antibody-drug conjugates.
Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
As reported in The Lancet by Lorusso et al, the phase III ROSELLA trial has shown an improvement in overall survival with the addition of relacorilant to nab-paclitaxel in patients with platinum-resistant ovarian cancer. Relacorilant is a selective glucocorticoid receptor antagonist that acts to...
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
Patients with advanced platinum-resistant ovarian cancer who had experienced disease progression on standard therapy exhibited clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial (ClinicalTrials.gov...
Researchers Identify Blood-Based Biomarker for Cancer Risk in People With Lynch Syndrome
Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help identify and characterize asymptomatic people with Lynch syndrome who are more susceptible to developing cancer based on early immune detection signatures, allowing clinicians...
Low-Risk Endometrial Cancer: Does a Lack of Adjuvant Therapy Affect Survival?
In a study reported in a research letter in JAMA Oncology, Matsuo et al found that survival without adjuvant therapy in women with low-risk endometrial cancer was poorer among those with isolated tumor cells (ITCs) vs no lymph node metastasis in regional lymph nodes. Study Details The cohort...
FDA Approves Relacorilant With Nab-Paclitaxel for Several Platinum-Resistant Gynecologic Cancers
On March 25, the U.S. Food and Drug Administration (FDA) approved relacorilant (Lifyorli), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received...
Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males
A population-level cohort study of 264.4 million deaths across 20 countries found that females born since the 1930s had higher cancer mortality than males between the ages of 35 and 60 years, largely due to breast and gynecologic cancers. Although females live longer than males on average, these...
Risk of Breast Cancer After Ovarian Cancer in Women With BRCA1/2 Variants
In a study reported in the Journal of Clinical Oncology, investigators from the Hereditary Breast Cancer Clinical Study Group found that women with ovarian cancer with pathogenic/likely pathogenic BRCA1/2 variants had low risk for subsequent breast cancer. Study Details The study involved an...
Recipients Named for the 2026 Pezcoller Foundation–AACR International Award
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Douglas R. Lowy, MD, and John T. Schiller, PhD, during the AACR Annual Meeting 2026, in San Diego. Drs. Lowy and Schiller Dr. Lowy is...
HPV Vaccination Protection From Cervical Cancer Sustained Long Term
Quadrivalent human papillomavirus (HPV) vaccination led to a significantly reduced risk of invasive cervical cancer that was sustained through long-term follow-up, according to the results of a Swedish nationwide, register-based cohort study published in The BMJ. “This study provides evidence of...
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence
Short-term exposure to low-dose vaginal estrogen therapy may relieve some symptoms of menopause for younger survivors of endometrial cancer without increasing the risk of endometrial cancer recurrence, according to findings from a study published in Menopause. “Early detection and improved,...
Research Suggests AI Pathology Models May Take Unreliable 'Shortcuts' to Identify Cancer Biomarkers
Artificial intelligence (AI) tools that detect molecular biomarker status from histologic images may be dependent upon correlational relationships with clinicopathologic features, preventing the models from learning the true causal effect of the biomarker, according to findings published in Nature...
FDA Approves Pembrolizumab With Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
On February 10, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor pembrolizumab (Keytruda) as well as pembrolizumab and the recombinant human enzyme,berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with paclitaxel, with or without bevacizumab. [Pembrolizumab plus...
Self-Acupressure May Ease Fatigue in Ovarian Cancer Survivors
In a phase III single-blind randomized clinical trial reported in JAMA Network Open, Zick et al found that self-acupressure—taught via a mobile app—provided a safe, low-cost approach for managing fatigue in ovarian cancer survivors. “In this randomized clinical trial, true self-acupressure and sham ...
